Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
AssigneeInnogenetics N.V.
InventorMithat Bozdayi
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues, both in vivo and in vitro. More in particular, reverse transcriptase mutant rtA181S is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti-viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described.
Claims27
An isolated HBV variant that comprises at least one nucleotide mutation in the DNA polymerase gene at codon position 181 which results in an alanine to serine amino acid substitution, rtA181S.
Dependencies are inferred from the claim text.